CTLA4 and cancer: In humans, hepatic lesions can be induced by anti-cancer immunotherapy (anti-PD-1 and anti-CTLA-4) and are associated with a predominant CD8 T cell infiltrate in the lobular zone, suggesting a reactivation of the local liver-antigen-specific T cell response67–69.